Brokers Issue Forecasts for MLTX FY2026 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings of ($3.78) per share for the year. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.13. During the same quarter last year, the business earned ($0.22) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. Wedbush reaffirmed an "outperform" rating and issued a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. The Goldman Sachs Group reduced their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $67.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of "Buy" and an average target price of $78.71.

MoonLake Immunotherapeutics Trading Down 4.1%

Shares of MoonLake Immunotherapeutics stock traded down $1.90 on Tuesday, reaching $44.17. 478,375 shares of the stock were exchanged, compared to its average volume of 381,505. The business has a fifty day moving average price of $39.62 and a two-hundred day moving average price of $43.78. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The firm has a market capitalization of $2.83 billion, a PE ratio of -34.24 and a beta of 1.23.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MLTX. Congress Asset Management Co. grew its holdings in MoonLake Immunotherapeutics by 9.5% during the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company's stock worth $3,953,000 after acquiring an additional 6,352 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in MoonLake Immunotherapeutics by 47.3% during the 4th quarter. Rice Hall James & Associates LLC now owns 111,133 shares of the company's stock worth $6,018,000 after acquiring an additional 35,664 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in MoonLake Immunotherapeutics by 3.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock worth $460,000 after acquiring an additional 320 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in MoonLake Immunotherapeutics by 18.4% during the 4th quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock worth $354,000 after acquiring an additional 1,013 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in MoonLake Immunotherapeutics by 5.8% during the 4th quarter. Sei Investments Co. now owns 22,025 shares of the company's stock worth $1,193,000 after acquiring an additional 1,202 shares in the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.